1. Home
  2. CNA vs UTHR Comparison

CNA vs UTHR Comparison

Compare CNA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNA
  • UTHR
  • Stock Information
  • Founded
  • CNA 1853
  • UTHR 1996
  • Country
  • CNA United States
  • UTHR United States
  • Employees
  • CNA N/A
  • UTHR N/A
  • Industry
  • CNA Property-Casualty Insurers
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNA Finance
  • UTHR Health Care
  • Exchange
  • CNA Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • CNA 13.2B
  • UTHR 14.4B
  • IPO Year
  • CNA N/A
  • UTHR 1999
  • Fundamental
  • Price
  • CNA $44.56
  • UTHR $305.61
  • Analyst Decision
  • CNA Sell
  • UTHR Buy
  • Analyst Count
  • CNA 2
  • UTHR 13
  • Target Price
  • CNA $50.50
  • UTHR $383.08
  • AVG Volume (30 Days)
  • CNA 697.7K
  • UTHR 367.9K
  • Earning Date
  • CNA 08-04-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • CNA 8.61%
  • UTHR N/A
  • EPS Growth
  • CNA N/A
  • UTHR 18.86
  • EPS
  • CNA 3.28
  • UTHR 25.10
  • Revenue
  • CNA $14,453,000,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • CNA N/A
  • UTHR $14.58
  • Revenue Next Year
  • CNA $24.00
  • UTHR $6.34
  • P/E Ratio
  • CNA $13.59
  • UTHR $12.17
  • Revenue Growth
  • CNA 6.34
  • UTHR 19.84
  • 52 Week Low
  • CNA $43.29
  • UTHR $266.98
  • 52 Week High
  • CNA $52.36
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • CNA 45.58
  • UTHR 58.66
  • Support Level
  • CNA $43.66
  • UTHR $290.80
  • Resistance Level
  • CNA $44.69
  • UTHR $302.52
  • Average True Range (ATR)
  • CNA 0.67
  • UTHR 6.50
  • MACD
  • CNA 0.07
  • UTHR 1.24
  • Stochastic Oscillator
  • CNA 47.39
  • UTHR 93.53

About CNA CNA Financial Corporation

CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: